Source: Eur Respir J 2010; 36: 808-818
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Dahal B.K., Kosanovic D., Pamarthi P.K., Sydykov A., Lai Y-J., Kast R., Schirok H., Stasch J-P., Ghofrani H.A., Weissmann N., Grimminger F., Seeger W., Schermuly R.T.. Therapeutic efficacy of azaindole-1 in experimental pulmonary hypertension. Eur Respir J 2010; 36: 808-818

Member's Comments

No comment yet.

Related content which might interest you: Enhanced efficacy of combining imatinib with sildenafil in a rodent model of pulmonary arterial hypertension Source: Annual Congress 2010 - Experimental pulmonary hypertension Year: 2010 Hemodynamical effects of metformin and sildenafil in the treatment of experimental pulmonary hypertension Source: International Congress 2019 – Pulmonary hypertension: clinical Year: 2019 Long-term safety and efficacy of imatinib in pulmonary arterial hypertension Source: Annual Congress 2012 - Pulmonary circulation: clinical treatment Year: 2012 New therapeutic approach for the treatment of monocrotaline-induced pulmonary hypertension with imatinib Source: Annual Congress 2010 - Pulmonary circulation I Year: 2010 Long-term safety of a new formulation of epoprostenol in pulmonary arterial hypertension Source: Annual Congress 2013 –Pulmonary circulation: clinical diagnosis, imaging, biomarkers and treatment Year: 2013 Long-term riociguat treatment towards implementing a targeted treatment strategy in patients with idiopathic pulmonary arterial hypertension Source: Virtual Congress 2020 – Epidemiology and treatment of pulmonary arterial hypertension Year: 2020 Clinical efficacy of oral sildenafil therapy in the treatment of pulmonary hypertension Source: Eur Respir J 2007; 30: Suppl. 51, 347s Year: 2007 Clinical trial design and new therapies for pulmonary arterial hypertension Source: Eur Respir J, 53 (1) 1801908; 10.1183/13993003.01908-2018 Year: 2019 Pharmacokinetic interactions of imatinib with bosentan and sildenafil for treatment of severe pulmonary arterial hypertension Source: Annual Congress 2013 –Pulmonary circulation: clinical treatment Year: 2013 Long-term safety and clinical effects of riociguat in chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension: Interim analysis of a phase II extension study Source: Annual Congress 2010 - Pulmonary hypertension updates Year: 2010 Safety and long-term efficacy of transition from sildenafil to tadalafil due to side effects in patients with pulmonary arterial hypertension Source: International Congress 2014 – Modern approach and old dilemmas in lung diseases Year: 2014 Safety and efficacy of bosentan in combination with sildenafil in pulmonary arterial hypertension: The COMPASS-3 study Source: Annual Congress 2011 - Treatments for pulmonary hypertension in human and experimental models Year: 2011 Novel therapeutic perspectives in pulmonary arterial hypertension Source: Eur Respir J 2003; 22: 193-194 Year: 2003 Combined treatment in pulmonary hypertension Source: International Congress 2016 – GR3 Scientific Grand Round: precision medicine Year: 2016 The therapeutic effects of zafirlukast on COPD induced pulmonary hypertension Source: Eur Respir J 2001; 18: Suppl. 33, 415s Year: 2001 Sitaxsentan treatment for patients with pulmonary arterial hypertension (PAH) failing bosentan due to lack of efficacy Source: Eur Respir J 2005; 26: Suppl. 49, 476s Year: 2005 Transitioning pulmonary arterial hypertension patients from bosentan to macitentan: efficacy and safety data. Source: International Congress 2017 – Outcomes and new treatment strategies in pulmonary hypertension Year: 2017 Long-term treatment of pulmonary hypertension with aerosolized iloprost Source: Eur Respir J 2001; 17: 8-13 Year: 2001 Rationale and study design of the RESPITE trial: Riociguat clinical effects studied in pulmonary arterial hypertension (PAH) patients with insufficient treatment response to PDE-5 inhibitors (PDE-5i) Source: International Congress 2015 – Pulmonary hypertension: novel clinical insights Year: 2015